Firms team up to develop cancer drugs in potential $540M deal

08/6/2013 | Reuters · Genetic Engineering & Biotechnology News

Bayer HealthCare and Compugen signed a preclinical research agreement centered on antibody-based cancer immunotherapies. Bayer will get the rights to further develop and market the drugs arising from the collaboration. The deal entitles Compugen to $10 million upfront and as much as $530 million in milestone fees plus sales royalties.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD